SCHEMBL5769479

SCHEMBL5769479

Clc1ccccc1C1=CCCN1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2A6 P11509 1/20 0.40
▸ MAPT P10636 1/20 0.37
▸ IDO1 P14902 1/20 0.36
▸ NPC1 O15118 3/20 0.35
▸ RAB9A P51151 3/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ TP53 P04637 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ LDHA P00338 1/20 0.35
▸ HTR7 P34969 2/20 0.35
▸ LMNA P02545 2/20 0.35
▸ TSHR P16473 1/20 0.35
▸ DPP4 P27487 1/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ POLB P06746 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ DCUN1D1 Q96GG9 1/20 0.34
▸ APOBEC3G Q9HC16 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13170396 0.76 NISCH (0.46) IDO1NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL12997917 0.76 IDO1 (0.35) IDO1
SCHEMBL30358065 0.76 ALDH1A1 (0.46) MAPTIDO1NPC1RAB9ASMN1; SMN2
SCHEMBL7163648 0.70 NISCH (0.39) MAPTNPC1HPGDTSHRALDH1A1
SCHEMBL31066557 0.69 POLB (0.35) CYP2A6MAPTIDO1NPC1RAB9A
Hydrochloric Acid SCHEMBL2855289 0.68 HTR6 (0.49) —
SCHEMBL10622635 0.68 CYP2A6 (0.40) CYP2A6MAPTIDO1NPC1RAB9A
SCHEMBL29883244 0.67 CYP2A6 (0.67) CYP2A6IDO1NPC1RAB9ASMN1; SMN2
SCHEMBL671133 0.67 CYP2A6 (0.67) CYP2A6IDO1NPC1RAB9ASMN1; SMN2
SCHEMBL29802156 0.67 CYP2A6 (0.67) CYP2A6IDO1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160794-A1 Tachykinin receptor antagonists ELI LILLY AND COMPANY 2006-07-20 — — US disclosed
EP-1638944-A1 TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2006-03-29 — — EP disclosed
WO-2005000821-A1 TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-01-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160794-A1 Tachykinin receptor antagonists TACR1, TACR2, PROKR1 CYP2A6 3531/4885MAPT 3578/4885IDO1 554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback